News from actavis plc A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

May 20, 2015, 16:05 ET

Actavis to Present at Bernstein's Thirty-First Annual Strategic Decisions Conference 2015

 Actavis plc (NYSE: ACT), a leading global pharmaceutical company, today announced that Brent Saunders, CEO and President of Actavis, will...

May 18, 2015, 08:00 ET

Actavis Launches NAMZARIC™ (memantine hydrochloride extended-release and donepezil hydrochloride), a Fixed-Dose Combination Therapy for the Treatment of Moderate to Severe Alzheimer's Disease

 Actavis plc (NYSE: ACT) today announced that NAMZARIC™ (memantine hydrochloride extended-release and donepezil hydrochloride), a...

May 12, 2015, 16:05 ET

Actavis to Present at UBS Global Healthcare Conference 2015

 Actavis plc (NYSE: ACT), a leading global pharmaceutical company, today announced that Brent Saunders, CEO and President of Actavis, will...

May 11, 2015, 06:30 ET

Actavis Reports Exceptional Performance in First Quarter 2015 with 59% Increase in Net Revenue to $4.2 Billion and 23% Growth in Non-GAAP EPS to $4.30

Actavis plc (NYSE: ACT) today reported continued exceptional performance with net revenue increasing 59 percent to $4.23 billion for the quarter...

May 07, 2015, 16:05 ET

Actavis to Re-launch Generic Pulmicort RESPULES® Following Favorable Appeals Court Ruling

 Actavis plc (NYSE: ACT) today announced that it will immediately re-launch its generic version of AstraZeneca's Pulmicort RESPULES®...

Apr 28, 2015, 16:15 ET

Actavis and Medicines360 Announce Publication of ACCESS IUS Efficacy and Safety Study of LILETTA™ (Levonorgestrel-Releasing Intrauterine System) 52 mg in Contraception

 Actavis plc (NYSE: ACT), a leading global pharmaceutical company and leader in women's health care, and Medicines360, a nonprofit women's...

Apr 24, 2015, 09:25 ET

Actavis Announces Topline Phase 3 Clinical Trial Results for Single-Dose DALVANCE® (dalbavancin) in the Treatment of ABSSSI

 Actavis plc (NYSE: ACT) today announced positive top-line results for study DUR001-303, a phase 3 study comparing a single 1500 mg dose of...

Apr 23, 2015, 08:00 ET

Actavis Launches AVYCAZ™ (Ceftazidime-Avibactam) Anti-Infective In U.S.

 Actavis plc (NYSE: ACT) today announced AVYCAZ™ (ceftazidime-avibactam) is now available for ordering by hospitals across the United...

Apr 20, 2015, 16:15 ET

Actavis Announces Retirement of Charles M. Mayr

Actavis plc (NYSE: ACT) today announced that Charles M. Mayr, Chief Communications Officer, will retire from Actavis on May 15, 2015 due...

Apr 20, 2015, 08:00 ET

Actavis Announces FDA Approval of Expanded Label for BOTOX® (OnabotulinumtoxinA) for the Treatment of Upper Limb Spasticity in Adults

 Actavis plc (NYSE: ACT), which recently completed the acquisition of Allergan, today announced that the United States Food and Drug...

Apr 16, 2015, 09:00 ET

Actavis to Host First Quarter 2015 Earnings Conference Call and Webcast

 Actavis plc (NYSE: ACT) today announced that it intends to release first quarter 2015 financial results on Monday, May 11, 2015, prior to the...

Apr 13, 2015, 09:22 ET

Actavis and Medicines360 Announce U.S. Availability of LILETTA™ (levonorgestrel-releasing intrauterine system) 52 mg to Prevent Pregnancy for up to Three Years

 Actavis plc (NYSE: ACT), a leading global pharmaceutical company and leader in women's health care, and Medicines360, a nonprofit women's...

Apr 08, 2015, 08:00 ET

Rhythm Initiates Phase 2b Clinical Trial of Relamorelin for Diabetic Gastroparesis

 Rhythm, a biopharmaceutical company, and Actavis plc (NYSE: ACT), a leading global pharmaceutical company, announced today the initiation of a...

Apr 03, 2015, 08:00 ET

Actavis Confirms Generic Letairis® Patent Challenge

 Actavis plc (NYSE: ACT) today confirmed that it has filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug...

Mar 17, 2015, 09:10 ET

Actavis Announces Michael R. Gallagher and Peter J. McDonnell to Join Board of Directors

 Actavis plc (NYSE: ACT) today announced that two former members of the Allergan Board of Directors - Michael R. Gallagher, Lead Independent...

Mar 17, 2015, 08:55 ET

Actavis Completes Allergan Acquisition

 Actavis plc (NYSE: ACT) today announced that it has completed the acquisition of Allergan, Inc. (NYSE: AGN) in a cash and equity transaction...

Mar 16, 2015, 16:05 ET

Actavis Receives FDA Approval for VIIBRYD® (vilazodone HCl) 20mg Once Daily as a Therapeutic Dose

 Actavis plc (NYSE: ACT) today announced the U.S. Food and Drug Administration (FDA) has approved a lower therapeutic dose of VIIBRYD®...

Mar 16, 2015, 10:21 ET

European Commission Clears Actavis' Pending Acquisition of Allergan

Actavis plc (NYSE: ACT) ("Actavis") and Allergan, Inc. (NYSE: AGN) ("Allergan") today announced that the companies received clearance from the...

Mar 13, 2015, 08:00 ET

Actavis Receives FDA Approval of SAPHRIS® for Pediatric Patients (age 10-17) for Acute Treatment of Manic or Mixed Episodes of Bipolar I Disorder

 Actavis plc (NYSE: ACT) today announced that the U.S. Food and Drug Administration (FDA) has approved its supplemental new drug application...

Mar 12, 2015, 17:00 ET

Actavis Confirms Appeals Court Grants Injunction Pending Appeal Related to Generic Pulmicort RESPULES®

 Actavis plc (NYSE: ACT) today confirmed that the United States Court of Appeals for the Federal Circuit has granted AstraZeneca's request for...